Celltrion unveils KRW 1.2 trillion Songdo expansion, boosting DS production capacity by 180,000L to a total of 570,000L Celltrion has unveiled an ambitious and far-reaching investment strategy aimed at significantly…
Eylea™ 8 mg Secures Approval in Japan for Its Third Retinal Disease Indication The Ministry of Health, Labour and Welfare (MHLW) has granted marketing authorization in Japan for Eylea 8…
Bristol Myers Squibb Strengthens Position in Obstructive Hypertrophic Cardiomyopathy with New Camzyos (mavacamten) Data Presented at ACC 2026 Bristol Myers Squibb has unveiled an extensive body of new clinical and…
Pfizer and Valneva Report Positive Phase 3 VALOR Results Showing High Efficacy for Lyme Disease Vaccine Candidate Pfizer Inc. and Valneva SE have announced encouraging topline findings from the pivotal…
Roche Launches State-of-the-Art Institute of Human Biology Facility to Advance Next-Generation Human Model Systems in Drug Discovery and Development Roche has officially inaugurated a new state-of-the-art research facility to serve…
Curi Bio and Battelle Forge Strategic Alliance to Advance New Approach Methods in Neuromuscular Pharmacology Curi Bio, a recognized leader in the development of human-relevant three-dimensional (3D) tissue platforms, has…
ImmunityBio Secures Macau SAR Authorization for ANKTIVA® in BCG-Unresponsive NMIBC with CIS With or Without Papillary Tumors ImmunityBio, today announced that the Pharmaceutical Administration Bureau (ISAF) of the Macau Special…
KalVista Pharmaceuticals to Showcase New Clinical Data on EKTERLY® (Sebetralstat) at the 2026 Global Angioedema Leadership Conference KalVista Pharmaceuticals has announced a significant scientific presence at the upcoming 2026 Global…
Newron Showcases Latest Research at the 2026 Schizophrenia International Research Society Annual Congress 2026 Newron Pharmaceuticals S.p.A., a clinical-stage biopharmaceutical company dedicated to advancing innovative therapies for disorders affecting the…
Bristol Myers Squibb Redefines First-Line Treatment Landscape in Classical Hodgkin Lymphoma with Expanded U.S. and EU Approvals for Opdivo® (nivolumab) Bristol Myers Squibb today announced that Opdivo® (nivolumab) has received approval for…
Novartis to Acquire Next-Generation Pan-Mutant PI3Kα Inhibitor, Enhancing Its Breast Cancer Treatment Pipeline Novartis has taken another significant step to strengthen its oncology pipeline, announcing a strategic agreement with Synnovation…
Board Reconstitution at Genmab A/S Accompanied by Employee Grants of Restricted Stock Units and Warrants Genmab A/S has announced key governance updates and employee incentive decisions following the conclusion of…
